SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after a preliminary update revealed that quarterly gross margins nearly doubled to 15-17% and record new orders topped 60 billion, fueling intense community speculation about an impending short squeeze. Investors are aggressively debating the sustainability of these margins and the massive backlog, with many optimistic that these results represent a pivotal shift in the company's valuation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending due to the announcement that Microsoft Azure will deploy its Helios AI rack-scale systems for large-scale model inference, intensifying competition in the data center hardware space. Community discourse remains divided between strong optimism regarding the company's expanding hyperscaler partnerships and skepticism from bears who point to potential overvaluation and earnings volatility ahead of the company's upcoming AI event.

JetBlue Airways Corp. engages in the provision of air transportation services. Its brands include jetBlue, jetBlue Vacations, Paisly, and TrueBlue. It operates through the following geographic segments: Domestic and Canada, Caribbean and Latin America, and Atlantic. The company was founded by David Gary Neeleman in August 1998 and is headquartered in Long Island City, NY.

Jetblue Airways Corp

JetBlue is trending following reports that the airline has engaged advisers to explore a potential sale or merger, fueling investor speculation about a possible acquisition by major carriers like United Airlines. The community is actively debating whether the airline's recent aggressive capacity adjustments and route network changes make it an attractive target or if its significant debt load and fuel cost pressures will continue to weigh on the share price.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is seeing significant momentum as investors leverage the company's energy exposure amid ongoing geopolitical instability in the Middle East and rising global crude prices. The community is closely watching technical breakouts and upcoming earnings, with active discussions focused on the potential for a sustained rally as markets react to supply constraints and the escalating conflict near key energy chokepoints.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony (UAMY) is trending following the wet commissioning of its Montana flotation mill and upcoming site visits from state leadership, fueling community discussion around its status as a key domestic critical mineral supplier. While investors are actively debating the stock's volatility and its strategic importance to defense supply chains, the community is focused on the tension between strong fundamental catalysts and persistent downward price pressure.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing a significant sell-off following reports that the Gemini 3.5 Pro model launch has been delayed due to coding performance shortfalls. The community is actively debating whether this is a temporary execution setback for a dominant AI infrastructure leader or a structural sign that Google is losing its competitive edge in the frontier model race.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is currently in the spotlight as investors weigh its aggressive pivot into 'Physical AI'including humanoid robotics and robotaxisagainst its core EV business. While the stock has seen volatility following recent earnings and mixed delivery sentiment, the community is debating whether the company will be re-rated as a technology and robotics platform rather than a traditional automaker.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending due to the completion of Phase 3 enrollment for its lead depression candidate HLP003 ahead of schedule, setting the stage for a major data readout in late 2026. The community remains focused on the potential for a breakthrough in adjunctive mental health treatments, though discourse is tempered by debates over cash runway and the firm's leadership transitions.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing extreme volatility as traders weigh heavy selling pressure against active short-covering and speculative buying ahead of a critical earnings week. The community remains deeply divided, with many debating whether the current price action represents a capitulation event or a temporary bounce within a broader bearish trend.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as the stock continues a strong upward trajectory, fueled by institutional accumulation and growing investor confidence ahead of the upcoming second-quarter earnings report. Community discussion is heavily focused on the potential for a short squeeze, the company's role as a leader in TIL therapy, and high expectations for future clinical data readouts in lung cancer, which traders view as a major catalyst for long-term value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think

Palantir (NASDAQ: PLTR) and Ginkgo Bioworks (NYSE: DNA) sit on opposite sides of a fast-emerging biosecurity debate. Palantir represents the intelligence layer, while Ginkgo represents the biological infrastructure layer. The question is whether future value comes from identifyin...

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings...

The $59B Quiet Shift Reshaping How Patients Access Care

The $59B Quiet Shift Reshaping How Patients Access Care The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026 Issued on behalf of VentriPoint Diagnostics...

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab Ginkgo Bioworks Reports First Quarter 2026 Financial Results...

Ginkgo Bioworks (NYSE:DNA) Stock Price Up 11.1% - What's Next?

Ginkgo Bioworks (NYSE:DNA) Trading Up 11.1% - What's Next...

Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation

Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation PR Newswire BOSTON, April 30, 2026 Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026BOSTON, April 30, 2026 /PRNewswire...

Ginkgo Bioworks (DNA) Projected to Post Quarterly Earnings on Tuesday

Ginkgo Bioworks (NYSE:DNA) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...

Ginkgo Bioworks (NYSE:DNA) Trading 6.9% Higher   - Here's What Happened

Ginkgo Bioworks (NYSE:DNA) Stock Price Up 6.9% - Still a Buy...

Short Interest in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Decreases By 23.2%

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totaling 6,146,646 shares, a...

Ginkgo Bioworks (NYSE:DNA) Insider Sells $212,626.11 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven Coen sold 33,171 shares of Ginkgo Bioworks stock in a transaction on Monday, April 13th. The stock was sold at an average price of $6.41, for a total value of $212,626.11. Following the completion of the sale, the insider...

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.89
Prev Close	$7.55
Open	$7.55
Dividend Yield	0.00%
50-Day Moving Average	$8.77
Beta	2.65
Avg. Volume	1.39M
PE Ratio	-1.46

52-Week High	$17.58
52-Week Low	$5.37
Market Capitalization	$493.2M
EPS (Annual)	-$5.64
Price to Book	1.04
Revenue Per Employee	$350,835.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNAGinkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Latest DNA News